Xilong Scientific Co., Ltd.
002584.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.78 | -2.99 | -0.86 | 0.14 |
| FCF Yield | 6.37% | -8.35% | -12.69% | 4.67% |
| EV / EBITDA | 24.74 | 42.04 | 20.09 | 19.03 |
| Quality | ||||
| ROIC | 2.41% | 1.08% | 4.75% | 10.42% |
| Gross Margin | 6.85% | 5.98% | 7.14% | 8.15% |
| Cash Conversion Ratio | 4.80 | -8.54 | -2.20 | 1.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.13% | 4.01% | -0.32% | 27.01% |
| Free Cash Flow Growth | 151.45% | 2.84% | -277.51% | 4,481.75% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 2.94 | 1.62 | -0.23 |
| Interest Coverage | 1.48 | 0.61 | 2.82 | 4.39 |
| Efficiency | ||||
| Inventory Turnover | 11.74 | 12.88 | 11.30 | 13.82 |
| Cash Conversion Cycle | 62.44 | 58.05 | 59.41 | 43.37 |